Tyra Biosciences is a brand-new company record, and its full research profile isn't ready yet.
tyra.bioCrawled Oct 26, 2026
TYRA’s pipeline focuses on small molecule drug discovery for oncology and genetically defined conditions, using structure-based design and internal kinase family insights.
– Financing led by Nextech Invest with participation from Cormorant Asset Management, BVF Partners, L.P., Janus Henderson Investors, and Logos, along with existing investors Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan
– Round co-led by Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan, representing a group of seasoned early-stage and crossover investors
Jake Simson is a Partner at RA Capital Management, investing in healthcare and life science companies. He serves on the boards of Xenikos, Janux, AavantiBio, and DiCE Molecules and holds degrees from MIT and Johns Hopkins University.
Melissa McCracken is a Principal at Nextech Invest, managing investments in cancer therapy companies. She previously worked at Third Rock Ventures and completed internships at Amgen.
Doug Warner joined TYRA as Chief Medical Officer in September 2024. He previously held leadership roles at Amgen for 18 years, overseeing clinical development for oncology and bone disease programs, including Vectibi.
Rehan Verjee has served as a member of our Board since June 2021. Mr. Verjee is currently the founding CEO of Precede Biosciences, a venture-backed, liquid-biopsy diagnostic company. Prior to founding Precede Biosciences, Mr. Verjee was a member of the Healthcare Executive Committee of Merck KGaA from October 2015 to March 2021. During this time, Mr. Verjee served as the President of EMD Serono and as the Chief Marketing and Strategy officer for the Healthcare business of Merck KGaA. As the Pres
TYRA’s proprietary discovery platform captures rapid, sequential structural snapshots of drug-target interactions to accelerate structure-based drug design.